GlobeNewsWire
03 Nov 2025, 12:00 UTC · 46w ago
Verdict
Headline takes no side. We score NMRA +0.20 across three claims — slightly bullish.
+0.20slightly bullish
More positive than 53% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Neumora Therapeutics expects a joint topline readout for KOASTAL-2 and -3 studies evaluating navacaprant in major depressive disorder in Q2 2026.
So whatTopline readouts for primary clinical trials are the most significant catalysts for biotech valuations.
More positive than 92% of claims this week
The company is progressing NMRA-511 for the treatment of Alzheimer’s disease agitation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 63% of claims this week
Neumora Therapeutics will participate in two investor conferences in November 2025.
So whatRoutine investor relations activity typically has negligible impact on stock price unless unexpected guidance is provided.
More positive than 42% of claims this week
Which stocks this story touches
More positive than 53% of ticker scores this week
The company is actively engaging with investors and providing updates on its clinical pipeline progress.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
17m ago
−75.8%
Price is moving against the score
$0.7313 vs $3.02 close before publication (Oct 31) · not market-adjusted
NMRA chart →
